Business Context and Reporting Period
Company: 60 Degrees Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 15, 2025
Reporting Period: The filing covers events occurring on July 15, 2025 (pricing) and July 16, 2025 (closing) regarding a capital raise.
Key Financial Metrics
This filing reports on a specific financing transaction rather than periodic operating results. Key metrics include:
- Gross Proceeds: Approximately $5.0 million.
- Offering Price: $1.90 per share of Common Stock and accompanying Warrants; $1.899 per Pre-Funded Warrant and accompanying Warrants.
- Securities Issued:
- 1,753,314 shares of Common Stock.
- 878,264 Pre-Funded Warrants.
- 878,264 Series A-1 Warrants.
- 878,264 Series A-2 Warrants.
- 197,368 Placement Agent Warrants.
- Use of Proceeds: General corporate purposes, including working capital.
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions outside of the proceeds from this specific offering.
Material Changes
The primary material change is the entry into a Securities Purchase Agreement for a best efforts follow-on offering. The Company raised approximately $5.0 million in gross proceeds, increasing its cash position pending the deduction of placement agent fees and offering expenses. The offering closed on July 16, 2025.
Guidance, Outlook, and Risks
Management Commentary: The Company intends to utilize net proceeds for general corporate purposes and working capital. The offering was conducted pursuant to a registration statement on Form S-1 declared effective on July 15, 2025.
Risks and Contingencies: The filing includes standard forward-looking statements cautioning that expectations regarding future results are based on current plans and may prove incorrect. No specific operational risks or contingencies beyond standard market and execution risks were detailed in this summary text.
Investor Verification Checklist
- Verify the final net proceeds after deducting placement agent fees and offering expenses.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and conditions.
- Examine the terms of the Series A-1 and A-2 Warrants (Exhibits 4.1 and 4.2) for exercise prices, expiration dates, and anti-dilution provisions.
- Confirm the impact of the new share issuance on existing shareholder dilution.
- Check subsequent filings for the actual cash balance post-closing.